C 23 H 19 FeN 3 O 3 S, monoclinic, P21/n (no. 14), a = 13.1372(6) Å,
Source of material
All reagents and solvents were purchased form commercial sources and used as received. A solution of 2-(4-methoxyphenyl)-1H-imidazo [4,5-b] pyridine (0.6 g, 2.7 mmol) in acetonitrile (18 mL) was added to a mixture of ferrocenylsulfonylchloride (0.72 g, 2.5 mmol) and anhydrous sodium 
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carbonate (0.26 g, 2.5 mmol) with constant stirring. The mixture was heated to re ux temperature for 48 h. The acetonitrile was evaporated under vacuum yielding a brown solid. The crude product was puri ed by column chromatography (SiO 2 , ethyl acetate petroleum ether v/v = 1:9) to give the title compound (0.25 g, 52% yield) as dark red crystals, mp: 483-485 K.
Experimental details
The crystal structure was solved by the direct methods. The hydrogen atoms were placed on calculated positions using the AFIX 43, 13 or 33 option of the SHELX-97 programm [6] .
Discussion
Imidazo [4,5-b] pyridine and their derivatives possess diverse pharmacological properties, including anticancer, antiviral, and other important biological activities [1] [2] [3] . The asymmetric unit of the title compound contains one title complex. There is a imidazo [4,5-b] pyridine and a sandwich ferrocene moiety in the structure. The imidazo [4,5-b] pyridine ring system (C11-C 16 ,N1-N 3 ) is planar, and its dihedral angle to the substituted cyclopentadienyl plane (C 6 -C 10 ) is 102.03(7)°. There are some di erences in bond lengths and bond angles between the substituted and unsubstituted cyclopentadienyl ring [4, 5] . The bond length of substituted cyclopentadienyl range from 1.412(3) to 1.431(2) Å, whereas in unsubstituted one the range is 1.397(3) to 1.418(3) Å.
